In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Hold rating on Virios Therapeutics (VIRI – Research Report). The company’s shares closed yesterday at $0.69.
According to TipRanks, Lee CFA is an analyst with an average return of -21.0% and a 23.53% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Monopar Therapeutics Inc, and Alphatec Holdings.
The word on The Street in general, suggests a Hold analyst consensus rating for Virios Therapeutics.
See today’s best-performing stocks on TipRanks >>
Based on Virios Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.44 million. In comparison, last year the company had a GAAP net loss of $3.67 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Virios Therapeutics (VIRI) Company Description:
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia.
Read More on VIRI:
- Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- VIRI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
- Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
- Virios Therapeutics terminates at-the-market sales agreement
